CALCIUM GLUCONATE
CALCIUM GLUCONATE is indicated for the treatment of Hypocalcemia.
Details
- Status
- Prescription
- First Approved
- 2017-06-15
- Patent Cliff
- 2037
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
CALCIUM GLUCONATE Approval History
What CALCIUM GLUCONATE Treats
1 indicationsCALCIUM GLUCONATE is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypocalcemia
CALCIUM GLUCONATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to CALCIUM GLUCONATE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
9 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05958342 CAVALIER | STUDY23040043 W81XWH-6-D-0024 | Ph 2 | recruiting | CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial |
| NCT05953376 | 3115 | Ph 3 | withdrawn | Empiric Calcium in Massive Transfusion |
| NCT07217899 | HUM00259931 | Ph 2 | recruiting | Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony |
| NCT06820645 CALM | 15231 | Ph 2, Ph 3 | not yet recruiting | Calcium Administration in Life-saving Management During Massive Hemorrhage |
| NCT01099449 results posted | N08CB NCCTG-N08CB, CDR0000669660 | Ph 3 | completed | Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy |
| NCT04958044 | eCaEP2021 | Ph 1 | completed | Endoscopic Assisted Calcium Electroporation in Esophageal Cancer |
| NCT02875587 | Cabergoline/calcium gluconate | Ph 2 | completed | Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome |
| NCT03473613 | Ashraf Elmantwe 1 | Ph 3 | completed | Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention |
| NCT00998738 results posted | RC08CC NCI-2009-01229, RC08CC | Ph 3 | terminated | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CALCIUM GLUCONATE FDA Label Details
Indications & Usage
FDA Label (PDF)CALCIUM GLUCONATE is indicated for the treatment of Hypocalcemia.
CALCIUM GLUCONATE Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for CALCIUM GLUCONATE
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2037
- • 6 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 3 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.